secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001641172-25-016388
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa enters $10M equity purchase agreement with Williamsburg Venture Holdings to fund VAR 200 clinical development
--------------------------------------------------------------------------------

- Up to $10M of common stock; company controls timing and amount of sales over 24-month term.
- Purchase price set at 94% of lowest VWAP during three trading days after each sale clears.
- 2.5% commitment fee in common shares, with piggyback registration rights; no warrants or derivatives.
- Funds intended to progress clinical development of Cholesterol Efflux Mediator TM VAR 200 for chronic kidney disease.
- Issuance capped at 19.99% of outstanding shares unless stockholder approval is obtained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000164117225016388/0001641172-25-016388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000164117225016388/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer